Bevacizumab for the first-line treatment of metastatic breast cancer

NICE technology appraisals [TA147] Published date:

Important information about this appraisal

Important information about this appraisal

This appraisal has been updated and replaced by NICE technology appraisal 214.

NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce technology appraisals guidance. Accreditation is valid for 5 years from September 2009 and applies to guidance produced since June 2008 using the processes described in NICE's 'The guide to the methods of technology appraisal' (2008). More information on accreditation can be viewed at www.nice.org.uk/accreditation
Get involved